94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Matilde Tubertini1,2
Luca Menilli3
Celeste Milani4Cecilia Martini1
Maria Luisa Navacchia1Marta Nugnes5
Manuela Bartolini5
Marina Naldi5
Daniele Tedesco1
Elisa Martella1Andrea Guerrini1
Claudia Ferroni1
Francesca Moret4*
Greta Varchi1*- 1Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Bologna, Italy
- 2Department of Science and High Technology, University of Insubria, Como, Italy
- 3Pharmacy Unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy
- 4Department of Biology (DiBio), University of Padova, Padua, Italy
- 5Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy
A Corrigendum on
HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy-an in vitro exploration
by Tubertini M, Menilli L, Milani C, Martini C, Navacchia ML, Nugnes M, Bartolini M, Naldi M, Tedesco D, Martella E, Guerrini A, Ferroni C, Moret F and Varchi G (2024). Front. Chem. 12:1378233. doi: 10.3389/fchem.2024.1378233
In the published article, there was an error in the Affiliation. Matilde Tubertini’s second affiliation was missing. The correct affiliations appear above.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: prodrugs, chemotherapy, IDO1 inhibition, endogenous human serum albumin, carrier-free nanoparticles, truncated evans blue, triple-negative breast cancer
Citation: Tubertini M, Menilli L, Milani C, Martini C, Navacchia ML, Nugnes M, Bartolini M, Naldi M, Tedesco D, Martella E, Guerrini A, Ferroni C, Moret F and Varchi G (2024) Corrigendum: HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy–an in vitro exploration. Front. Chem. 12:1443822. doi: 10.3389/fchem.2024.1443822
Received: 04 June 2024; Accepted: 05 June 2024;
Published: 18 June 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Tubertini, Menilli, Milani, Martini, Navacchia, Nugnes, Bartolini, Naldi, Tedesco, Martella, Guerrini, Ferroni, Moret and Varchi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Greta Varchi, Z3JldGEudmFyY2hpQGlzb2YuY25yLml0; Francesca Moret, ZnJhbmNlc2NhLm1vcmV0QHVuaXBkLml0